Rethinking the medication management of major depression

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Major Depressive Disorder (MDD) is a leading global health burden.
• Current MDD treatments have modest initial response rates that decline significantly over time.
• Existing guidelines recommend sequential monotherapy, leaving many patients with persistent depression.

Purpose of the Study:

• To critically re-examine current MDD treatment strategies.
• To propose an evidence-based algorithm, the Accelerated Sequential Antidepressant Protocol (ASAP), for optimizing early treatment response.
• To suggest future research directions, including comparisons with existing guidelines and the role of novel agents like ketamine.

Main Methods:

• Systematic literature search of PubMed for randomized controlled trials comparing antidepressant combinations versus monotherapy up to June 2021.
• Analysis of findings in the context of current MDD treatment guidelines.
• Development of the ASAP algorithm based on evidence for optimizing early treatment phases.

Main Results:

• Current treatment guidelines, involving sequential six-week monotherapy trials, result in approximately one-third of patients remaining depressed after six months.
• Response rates are significantly higher in the initial three months of treatment compared to the subsequent three months.
• The proposed ASAP algorithm utilizes shorter medication trials (2-4 weeks) and earlier introduction of antidepressant combinations.

Conclusions:

• Optimizing the first three months of MDD treatment is critical for improving overall outcomes.
• The ASAP protocol offers a potential strategy to enhance treatment response by shortening trial durations and facilitating earlier combination therapy.
• Further research is warranted to validate ASAP against current guidelines and explore the utility of rapidly acting antidepressants for severe MDD cases.